Long-term clinical and visual outcomes after surgical resection of pediatric pilocytic/pilomyxoid optic pathway gliomas
Hidalgo, Eveline Teresa; Kvint, Svetlana; Orillac, Cordelia; North, Emily; Dastagirzada, Yosef; Chang, Jamie Chiapei; Addae, Gifty; Jennings, Tara S; Snuderl, Matija; Wisoff, Jeffrey H
OBJECTIVEThe choice of treatment modality for optic pathway gliomas (OPGs) is controversial. Chemotherapy is widely regarded as first-line therapy; however, subtotal resections have been reported for decompression or salvage therapy as first- and second-line treatment. The goal of this study was to further investigate the role and efficacy of resection for OPGs.METHODSA retrospective chart review was performed on 83 children who underwent surgical treatment for OPGs between 1986 and 2014. Pathology was reviewed by a neuropathologist. Clinical outcomes, including progression-free survival (PFS), overall survival (OS), and complications, were analyzed.RESULTSThe 5- and 10-year PFS rates were 55% and 46%, respectively. The 5- and 10-year OS rates were 87% and 78%, respectively. The median extent of resection was 80% (range 30%-98%). Age less than 2 years at surgery and pilomyxoid features of the tumor were found to be associated with significantly lower 5-year OS. No difference was seen in PFS or OS of children treated with surgery as a first-line treatment compared with children with surgery as a second- or third-line treatment. Severe complications included new disabling visual deficit in 5%, focal neurological deficit in 8%, and infection in 2%. New hormone deficiency occurred in 22% of the children.CONCLUSIONSApproximately half of all children experience a long-term benefit from resection both as primary treatment and as a second-line therapy after failure of primary treatment. Primary surgery does not appear to have a significant benefit for children younger than 2 years or tumors with pilomyxoid features. Given the risks associated with surgery, an interdisciplinary approach is needed to tailor the treatment plan to the individual characteristics of each child.
Invasive monitoring after resection of epileptogenic neocortical lesions in multistaged epilepsy surgery in children
Hidalgo, Eveline Teresa; Frankel, Hyman Gregory; Rodriguez, Crystalann; Orillac, Cordelia; Phillips, Sophie; Patel, Neel; Devinsky, Orrin; Friedman, Daniel; Weiner, Howard L
OBJECTIVE:Incomplete resection of neocortical epileptogenic foci correlates with failed epilepsy surgery in children. We often treat patients with neocortical epilepsy with a staged approach using invasive monitoring to localize the focus, resect the seizure onset zone, and, in select cases, post-resection invasive monitoring (PRM). We report the technique and the outcomes of children treated with staged surgery including PRM. METHODS:We retrospectively reviewed the charts of pediatric patients with neocortical epilepsy who underwent resective surgery with PRM. RESULTS:We identified 71 patients, 5 patients with MRI-negative epilepsy and 66 patients with MRI-identified neocortical lesions; 64/66 (97%) patients had complete lesionectomy. In 61/71 (86%) patients PRM was associated with positive outcomes. Those findings were: 1) clinical seizures with electrographic involvement at resection margins (47%); 2) subclinical seizures and interictal discharges at resection margins (29%); and 3) clinical and subclinical seizures revealing a new epileptogenic focus (20%). In 55/71 (77%) patients, PRM data led to additional resection (re-resection; RR). Six additional patients had no further resection due to overlap with eloquent cortex. Histopathology showed tuberous sclerosis complex (TSC; nâ€‰=â€‰46), focal cortical dysplasia (FCD; nâ€‰=â€‰16)), gliosis (nâ€‰=â€‰4), tumors (nâ€‰=â€‰4), and Sturge-Weber syndrome (nâ€‰=â€‰1). There were no major complications. Seizure-free outcome in children with TSC was 63% at 1-year follow-up and 56% at 2-year follow-up. In FCD, seizure freedom after 1 and 2 years was 85%. SIGNIFICANCE/CONCLUSIONS:Post-resection monitoring may provide additional information about the extent of the epileptogenic zone, such as residual epileptogenic activity at the margins of the resection cavity, and may unmask additional seizure foci. This method may be especially useful in achieving long-term stable seizure-free outcome.
Subgroup-specific outcomes of children with malignant childhood brain tumors treated with an irradiation-sparing protocol
Hidalgo, Eveline Teresa; Snuderl, Matija; Orillac, Cordelia; Kvint, Svetlana; Serrano, Jonathan; Wu, Peter; Karajannis, Matthias A; Gardner, Sharon L
PURPOSE/OBJECTIVE:Molecular subgroups of pediatric brain tumors associated with divergent biological, clinical, and prognostic features have been identified. However, data regarding the impact of subgroup affiliation on the outcome of children with malignant brain tumors treated with radiation-sparing protocol is limited. We report long-term clinical outcomes and the molecular subgroups of malignant brain tumors in young children whose first-line treatment was high-dose chemotherapy without irradiation. METHODS:Tumor subclassification was performed using the Illumina HumanMethylation450 BeadChip (450k) genome-wide methylation array profiling platform.Â Clinical information was obtained from chart review. RESULTS:Methylation array profiling yielded information on molecular subgroups in 22 children. Median age at surgery was 26Â months (range 1-119Â months). Among medulloblastomas (MB), all 6 children in the infant sonic hedgehog (SHH) subgroup were long-term survivors, whereas all 4 children in subgroup 3 MB died. There was one long-term survivor in subgroup 4 MB. One out of five children with ependymoma was a long-term survivor (RELPOS). Both children with primitive neuroectodermal tumors died. One child with ATRT TYR and one child with choroid plexus carcinoma were long-term survivors. CONCLUSIONS:The efficacy of high-dose chemotherapy radiation-sparing treatment appears to be confined to favorable molecular subgroups of pediatric brain tumors, such as infant SHH MB. Identification of molecular subgroups that benefit from radiation-sparing therapy will aid in the design of prospective, "precision medicine"-driven clinical trials.
Clinical, Pathological, and Molecular Characteristics of Diffuse Spinal Cord Gliomas
Garcia, Mekka R; Feng, Yang; Vasudevaraja, Varshini; Galbraith, Kristyn; Serrano, Jonathan; Thomas, Cheddhi; Radmanesh, Alireza; Hidalgo, Eveline T; Harter, David H; Allen, Jeffrey C; Gardner, Sharon L; Osorio, Diana S; William, Christopher M; Zagzag, David; BouÃ©, Daniel R; Snuderl, Matija
Diffuse spinal cord gliomas (SCGs) are rare tumors associated with a high morbidity and mortality that affect both pediatric and adult populations. In this retrospective study, we sought to characterize the clinical, pathological, and molecular features of diffuse SCG in 22 patients with histological and molecular analyses. The median age of our cohort was 23.64â€‰years (range 1-82) and the overall median survival was 397â€‰days. K27M mutation was significantly more prevalent in males compared to females. Gross total resection and chemotherapy were associated with improved survival, compared to biopsy and no chemotherapy. While there was no association between tumor grade, K27M status (pâ€‰=â€‰0.366) or radiation (pâ€‰=â€‰0.772), and survival, males showed a trend toward shorter survival. K27M mutant tumors showed increased chromosomal instability and a distinct DNA methylation signature.
DNA Methylation Profiling Identifies Epigenetic Subclasses of Focal Cortical Dysplasia In Treatment-Resistant Epilepsy [Meeting Abstract]
Movahed-Ezazi, Misha; Vasudeyaraja, Varshini; Tran, Ivy; Dastagirzada, Yosef; Pelorosso, Cristiana; Conti, Valerio; Guerrini, Renzo; Buccoliero, Anna Maria; Friedman, Daniel; Devinsky, Orrin; Hidalgo, Eveline; Snuderl, Matija
Clinical value of DNA methylation in practice: A prospective molecular neuropathology study [Meeting Abstract]
Galbraith, Kristyn; Shen, Guomiao; Serrano, Jonathan; Vasudevaraja, Varshini; Tran, Ivy; Movahed-Ezazi, Misha; Harter, David; Hidalgo, Eveline; Wisoff, Jeffrey; Orringer, Daniel; Placantonakis, Dimitris; Gardner, Sharon; William, Christopher; Zagzag, David; Allen, Jeffrey; Sulman, Erik; Golfinos, John; Snuderl, Matija
Comparison of the real-world effectiveness of vertical versus lateral functional hemispherotomy techniques for pediatric drug-resistant epilepsy: A post hoc analysis of the HOPS study
Fallah, Aria; Lewis, Evan; Ibrahim, George M; Kola, Olivia; Tseng, Chi-Hong; Harris, William B; Chen, Jia-Shu; Lin, Kao-Min; Cai, Li-Xin; Liu, Qing-Zhu; Lin, Jiu-Luan; Zhou, Wen-Jing; Mathern, Gary W; Smyth, Matthew D; O'Neill, Brent R; Dudley, Roy W R; Ragheb, John; Bhatia, Sanjiv; Delev, Daniel; Ramantani, Georgia; Zentner, Josef; Wang, Anthony C; Dorfer, Christian; Feucht, Martha; Czech, Thomas; Bollo, Robert J; Issabekov, Galymzhan; Zhu, Hongwei; Connolly, Mary; Steinbok, Paul; Zhang, Jian-Guo; Zhang, Kai; Hidalgo, Eveline Teresa; Weiner, Howard L; Wong-Kisiel, Lily; Lapalme-Remis, Samuel; Tripathi, Manjari; Sarat Chandra, Poodipedi; Hader, Walter; Wang, Feng-Peng; Yao, Yi; Champagne, Pierre-Olivier; Brunette-Clément, Tristan; Guo, Qiang; Li, Shao-Chun; Budke, Marcelo; Pérez-Jiménez, Maria Angeles; Raftopoulos, Christian; Finet, Patrice; Michel, Pauline; Schaller, Karl; Stienen, Martin N; Baro, Valentina; Cantillano Malone, Christian; Pociecha, Juan; Chamorro, Noelia; Muro, Valeria L; von Lehe, Marec; Vieker, Silvia; Oluigbo, Chima; Gaillard, William D; Al-Khateeb, Mashael; Al Otaibi, Faisal; KrayenbÃ¼hl, Niklaus; Bolton, Jeffrey; Pearl, Phillip L; Weil, Alexander G
OBJECTIVE:This study was undertaken to determine whether the vertical parasagittal approach or the lateral peri-insular/peri-Sylvian approach to hemispheric surgery is the superior technique in achieving long-term seizure freedom. METHODS:We conducted a post hoc subgroup analysis of the HOPS (Hemispheric Surgery Outcome Prediction Scale) study, an international, multicenter, retrospective cohort study that identified predictors of seizure freedom through logistic regression modeling. Only patients undergoing vertical parasagittal, lateral peri-insular/peri-Sylvian, or lateral trans-Sylvian hemispherotomy were included in this post hoc analysis. Differences in seizure freedom rates were assessed using a time-to-eventÂ method andÂ calculated using the Kaplan-Meier survival method. RESULTS:Data for 672 participants across 23 centers were collected on the specific hemispherotomy approach. Of these, 72 (10.7%) underwent vertical parasagittalÂ hemispherotomy and 600 (89.3%) underwent lateral peri-insular/peri-Sylvian or trans-Sylvian hemispherotomy. Seizure freedom was obtained in 62.4% (95% confidence interval [CI]Â =Â 53.5%-70.2%) of the entire cohort at 10-year follow-up. Seizure freedom was 88.8% (95% CIÂ =Â 78.9%-94.3%) at 1-year follow-up and persisted at 85.5% (95% CIÂ =Â 74.7%-92.0%) across 5- and 10-year follow-up in the vertical subgroup. In contrast, seizure freedom decreased from 89.2% (95% CIÂ =Â 86.3%-91.5%) at 1-year to 72.1% (95% CIÂ =Â 66.9%-76.7%) at 5-year to 57.2% (95% CIÂ =Â 46.6%-66.4%) at 10-year follow-up for the lateral subgroup. Log-rank test found that vertical hemispherotomy was associated with durable seizure-free progression compared to the lateral approach (pÂ =Â .01). Patients undergoing the lateral hemispherotomy technique had a shorter time-to-seizure recurrence (hazard ratioÂ =Â 2.56, 95% CIÂ =Â 1.08-6.04, pÂ =Â .03) and increased seizure recurrence odds (odds ratioÂ =Â 3.67, 95% CIÂ =Â 1.05-12.86, pÂ =Â .04) compared to those undergoing the vertical hemispherotomy technique. SIGNIFICANCE/CONCLUSIONS:This pilot study demonstrated more durable seizure freedom of the vertical technique compared to lateral hemispherotomy techniques. Further studies, such as prospective expertise-based observational studies or aÂ randomized clinical trial, are required to determine whether a vertical approach to hemispheric surgery provides superior long-term seizure outcomes.
Pediatric midline H3K27M-mutant tumor with disseminated leptomeningeal disease and glioneuronal features: case report and literature review
Navarro, Ralph E; Golub, Danielle; Hill, Travis; McQuinn, Michelle W; William, Christopher; Zagzag, David; Hidalgo, Eveline Teresa
BACKGROUND:H3K27M-mutant midline lesions were recently reclassified by the World Health Organization (WHO) as "diffuse midline glioma" (DMG) based entirely on their molecular signature. DMG is one of the most common and most lethal pediatric brain tumors; terminal progression is typically caused by local midbrain or brainstem progression, or secondary leptomeningeal dissemination. H3K27M mutations have also been infrequently associated with a histologically and prognostically diverse set of lesions, particularly spinal masses with early leptomeningeal spread. CASE PRESENTATION/METHODS:A 15-year-old girl after 1Â week of symptoms was found to have a T2/FLAIR-hyperintense and contrast-enhancing thalamic mass accompanied by leptomeningeal enhancement along the entire neuraxis. Initial infectious workup was negative, and intracranial biopsy was inconclusive. Spinal arachnoid biopsy revealed an H3K27M-mutant lesion with glioneuronal features, classified thereafter as DMG. She received craniospinal irradiation with a boost to the thalamic lesion. Imaging 1-month post-radiation demonstrated significant treatment response with residual enhancement at the conus. CONCLUSIONS:This case report describes the unique presentation of an H3K27M-mutant midline lesion with significant craniospinal leptomeningeal spread on admission and atypical glioneuronal histopathological markers. With such florid leptomeningeal disease, spinal dural biopsy should be considered earlier given its diagnostic yield in classifying the lesion as DMG. Consistent with similar prior reports, this lesion additionally demonstrated synaptophysin positivity-also potentially consistent with a diagnosis of diffuse leptomeningeal glioneuronal tumor (DLGNT). In atypical DMG cases, particularly with leptomeningeal spread, further consideration of clinical and histopathological context is necessary for accurate diagnosis and prognostication.
Hemispherectomy Outcome Prediction Scale: Development and validation of a seizure freedom prediction tool
Weil, Alexander G; Lewis, Evan C; Ibrahim, George M; Kola, Olivia; Tseng, Chi-Hong; Zhou, Xinkai; Lin, Kao-Min; Cai, Li-Xin; Liu, Qing-Zhu; Lin, Jiu-Luan; Zhou, Wen-Jing; Mathern, Gary W; Smyth, Matthew D; O'Neill, Brent R; Dudley, Roy; Ragheb, John; Bhatia, Sanjiv; Delev, Daniel; Ramantani, Georgia; Zentner, Josef; Ojemann, Jeffrey; Wang, Anthony C; Dorfer, Christian; Feucht, Martha; Czech, Thomas; Bollo, Robert J; Issabekov, Galymzhan; Zhu, Hongwei; Connelly, Mary; Steinbok, Paul; Zhang, Jian-Guo; Zhang, Kai; Hidalgo, Eveline Teresa; Weiner, Howard L; Wong-Kisiel, Lily; Lapalme-Remis, Samuel; Tripathi, Manjari; Sarat Chandra, Poodipedi; Hader, Walter; Wang, Feng-Peng; Yao, Yi; Olivier Champagne, Pierre; Guo, Qiang; Li, Shao-Chun; Budke, Marcelo; Pérez-Jiménez, Maria Angeles; Raftapoulos, Christian; Finet, Patrice; Michel, Pauline; Schaller, Karl; Stienen, Martin N; Baro, Valentina; Cantillano Malone, Christian; Pociecha, Juan; Chamorro, Noelia; Muro, Valeria L; von Lehe, Marec; Vieker, Silvia; Oluigbo, Chima; Gaillard, William D; Al Khateeb, Mashael; Al Otaibi, Faisal; KrayenbÃ¼hl, Niklaus; Bolton, Jeffrey; Pearl, Phillip L; Fallah, Aria
OBJECTIVE:To develop and validate a model to predict seizure freedom in children undergoing cerebral hemispheric surgery for the treatment of drug-resistant epilepsy. METHODS:We analyzed 1267 hemispheric surgeries performed in pediatric participants across 32 centers and 12 countries to identify predictors of seizure freedom at 3 months after surgery. A multivariate logistic regression model was developed based on 70% of the dataset (training set) and validated on 30% of the dataset (validation set). Missing data were handled using multiple imputation techniques. RESULTS:Overall, 817 of 1237 (66%) hemispheric surgeries led to seizure freedom (median follow-up = 24Â months), and 1050 of 1237 (85%) were seizure-free at 12Â months after surgery. A simple regression model containing age at seizure onset, presence of generalized seizure semiology, presence of contralateral 18-fluoro-2-deoxyglucose-positron emission tomography hypometabolism, etiologic substrate, and previous nonhemispheric resective surgery is predictive of seizure freedom (area under the curve = .72). A Hemispheric Surgery Outcome Prediction Scale (HOPS) score was devised that can be used to predict seizure freedom. SIGNIFICANCE/CONCLUSIONS:Children most likely to benefit from hemispheric surgery can be selected and counseled through the implementation of a scale derived from a multiple regression model. Importantly, children who are unlikely to experience seizure control can be spared from the complications and deficits associated with this surgery. The HOPS score is likely to help physicians in clinical decision-making.
Somatic Focal Copy Number Gains of Noncoding Regions of Receptor Tyrosine Kinase Genes in Treatment-Resistant Epilepsy
Vasudevaraja, Varshini; Rodriguez, Javier Hernaez; Pelorosso, Cristiana; Zhu, Kaicen; Buccoliero, Anna Maria; Onozato, Maristela; Mohamed, Hussein; Serrano, Jonathan; Tredwin, Lily; Garonzi, Marianna; Forcato, Claudio; Zeck, Briana; Ramaswami, Sitharam; Stafford, James; Faustin, Arline; Friedman, Daniel; Hidalgo, Eveline Teresa; Zagzag, David; Skok, Jane; Heguy, Adriana; Chiriboga, Luis; Conti, Valerio; Guerrini, Renzo; Iafrate, A John; Devinsky, Orrin; Tsirigos, Aristotelis; Golfinos, John G; Snuderl, Matija
Epilepsy is a heterogenous group of disorders defined by recurrent seizure activity due to abnormal synchronized activity of neurons. A growing number of epilepsy cases are believed to be caused by genetic factors and copy number variants (CNV) contribute to up to 5% of epilepsy cases. However, CNVs in epilepsy are usually large deletions or duplications involving multiple neurodevelopmental genes. In patients who underwent seizure focus resection for treatment-resistant epilepsy, whole genome DNA methylation profiling identified 3 main clusters of which one showed strong association with receptor tyrosine kinase (RTK) genes. We identified focal copy number gains involving epidermal growth factor receptor (EGFR) and PDGFRA loci. The dysplastic neurons of cases with amplifications showed marked overexpression of EGFR and PDGFRA, while glial and endothelial cells were negative. Targeted sequencing of regulatory regions and DNA methylation analysis revealed that only enhancer regions of EGFR and gene promoter of PDGFRA were amplified, while coding regions did not show copy number abnormalities or somatic mutations. Somatic focal copy number gains of noncoding regulatory represent a previously unrecognized genetic driver in epilepsy and a mechanism of abnormal activation of RTK genes. Upregulated RTKs provide a potential avenue for therapy in seizure disorders.